Issue 78

MM-120

MindMed, MM-120 and Dynamic Drug Development

At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for the largest commercial study of LSD ever conducted.

Topline data from a landmark Phase IIa trial will be presented at May’s PSYCH Symposium, with the CEO of MindMed, Robert Barrow, joining a panel to discuss the company’s approach to drug development.

Ahead of the seminal event, PSYCH spoke with Barrow about studies of the proprietary compound and its potential applications.

READ MORE

MAKING PSILOCYBIN AVAILABLE TO UK CANCER PATIENTS

Psychedelic medicines have been cited as a treatment for associated anxiety and depression.

Read More

OREGON TO ONLY ALLOW CULTIVATION OF PSILOCYBE CUBENSIS

State officials have proposed regulating only one type of hallucinogenic mushroom in 2023 for therapeutic use.

Read More

BUSINESS AND INVESTMENT

Biomind doses first subject in Phase I/II clinical trial.

Filament Health has been issued with fourth patent for natural psychedelic medicines.

MYND Life Sciences announces share offering.

MINDCURE shares quarterly financial results.

Cybin partners with Clinilabs Drug Development Corporation for clinical trials.

Nirvana announces production of psilocybin and psilocin.

NHS psychiatrist decries lack of mental health beds.

Are psychedelic medicines the answer to the mental health crisis?

How VR could be used in psychedelic-assisted therapy.

PSYCH Symposium: London 2022

With only two weeks to go, tickets for Europe’s premier psychedelic healthcare conference are selling fast.

Register today to connect with decision makers and contribute to the future of psychedelic medicine in Europe.

Speakers include:

Professor Matthias Liechti – University Hospital Basel
Dr Anne Katrin Schlag – Drug Science
Professor Bryan Roth – DARPA

REGISTER YOUR TICKET

SCIENCE AND RESEARCH

Psychedelic medicines may alter perceptions of consciousness.

Could psilocybin help with depression?

REGULATION AND LEGISLATION

Maine Senate approves bill to create medicinal psilocybin programme.

Partner with us